Targeted immune suppression versus cell-based immune modulation
Quick answer
Biologics in rheumatoid arthritis block a specific inflammatory signal such as TNF-alpha or IL-6. RASTEM, a cell drug in EHL Bio's pipeline, instead aims to modulate immune balance through the factors the cells secrete. The two are not interchangeable, and both belong under a rheumatologist's care.
Biologics deliver measurable benefit in many patients, but they carry infection risk from immune suppression, require ongoing dosing, and can lose effect when anti-drug antibodies develop. That gap is why cell-based approaches attract interest in poor responders.
MSCs do not switch the immune system off. They release factors that nudge immune cells to behave differently — expanding regulatory T cells and lowering inflammatory mediators. It is redirection rather than blanket suppression, which in theory gives a different infection-risk profile from classic immunosuppressants.
Practically, do not stop your prescribed medication to pursue cell therapy. Self-discontinuation in rheumatoid arthritis risks flares and permanent joint damage. The safe plan is joint assessment with your treating physician and follow-up on ESR, CRP and DAS28.
No — treat it as an adjunct under medical supervision, not a reason to stop existing therapy.
The mechanism differs — modulation rather than broad suppression — but individual risk still needs assessment and monitoring.
Last updated: 2026-08-28 · This content is for information only and is not medical advice. Consult a qualified doctor before making treatment decisions.
Back to categoriesRelated topics: Cell drug pipeline · Joints & immunity